Table 1 Clinical trials on anti-Tim-3 agents
From: Tim-3 expression and its role in hepatocellular carcinoma
NCT number | Anti-Tim-3 agents | Combining agent | Mechanism of combining agents | Patients | Diseases | Phases |
|---|---|---|---|---|---|---|
03489343 | Sym023 | – | – | 48 | Metastatic cancer Solid tumor Lymphoma | Phase 1 |
02817633 | TSR-022 | – | – | 627 | Advanced or metastatic solid tumors | Phase 1 |
02608268 | MBG453 | PDR001 | Anti-PD-1 | 250 | Advanced or metastatic solid tumors | Phase 1 and 2 |
03066648 | MBG453 | PDR001, Decitabine | Anti-PD-1, inhibit DNA methyltransferase | 70 | Leukemia Leukemia, myeloid Leukemia, myeloid, acute Myelodysplastic syndromes Preleukemia Bone marrow diseases Hematologic diseases | Phase 1 |
03099109 | LY3321367 | LY3300054 | Anti-PD-1 | 172 | Solid tumor | Phase 1 |